Literature DB >> 15590933

Role of alpha-synuclein in presynaptic dopamine recruitment.

Leonid Yavich1, Heikki Tanila, Saila Vepsäläinen, Pekka Jäkälä.   

Abstract

Real-time monitoring of stimulated dopamine release in mice with different alpha-synuclein expression was used to study the role of alpha-synuclein in presynaptic dopamine recruitment. Repeated electrical stimulations of ascending dopaminergic pathways decreased the capacity of the readily releasable pool (RRP) and temporarily increased its refilling rate, significantly slowing the rate of dopamine decline in mice with normally expressed alpha-synuclein. Mice with alpha-synuclein null mutation demonstrated a permanent increase of the refilling rate. This increase maintained stable dopamine release during stimulation (which induced dopamine decline in other animals) and served as an adaptation to altered dopamine compartmentalization. Mice without alpha-synuclein and with overexpression of human A30P mutated alpha-synuclein had a lower capacity of the dopamine storage pool than other animals. Reducing capacity of the storage pool in transgenic A30P mice led to paradoxical effects of l-dopa, which elevated dopamine release in response to single stimulation but decreased the refilling rate of the RRP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15590933      PMCID: PMC6730279          DOI: 10.1523/JNEUROSCI.2559-04.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  116 in total

1.  Effects of curvature and composition on α-synuclein binding to lipid vesicles.

Authors:  Elizabeth R Middleton; Elizabeth Rhoades
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 3.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 4.  Dynamic structural flexibility of α-synuclein.

Authors:  Danielle E Mor; Scott E Ugras; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Neurobiol Dis       Date:  2015-12-31       Impact factor: 5.996

5.  Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis.

Authors:  James H Soper; Victoria Kehm; Christopher G Burd; Vytas A Bankaitis; Virginia M-Y Lee
Journal:  J Mol Neurosci       Date:  2010-10-02       Impact factor: 3.444

Review 6.  The physiological role of α-synuclein and its relationship to Parkinson's Disease.

Authors:  David Sulzer; Robert H Edwards
Journal:  J Neurochem       Date:  2019-07-28       Impact factor: 5.372

Review 7.  On the key role played by altered protein conformation in Parkinson's disease.

Authors:  L F Agnati; E Baldelli; N Andreoli; A S Woods; V Vellani; D Marcellino; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

8.  Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model.

Authors:  Kerstin K Landrock; Patti Sullivan; Heidi Martini-Stoica; David S Goldstein; Brett H Graham; Shinya Yamamoto; Hugo J Bellen; Richard A Gibbs; Rui Chen; Marcello D'Amelio; George Stoica
Journal:  Brain Res       Date:  2017-12-05       Impact factor: 3.252

Review 9.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

10.  Analysis of exon dosage using MLPA in South African Parkinson's disease patients.

Authors:  Rowena J Keyser; Debbie Lombard; Rene Veikondis; Jonathan Carr; Soraya Bardien
Journal:  Neurogenetics       Date:  2009-12-15       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.